Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Presently, there remains no consensus on the optimal management of a patient with a high or intermediate-risk massive pulmonary embolism (PE). Treatment offered is varied and dependant on patient presentation, local guidelines and available local expertise. Despite the availability of various clinical parameters (blood pressure, tachycardia, hypoxia), biochemical markers (Troponin T or I, BNP), and imaging tools (echocardiographic, CT or MRI criteria) which facilitate the diagnosis and risk stratification of a PE, uniformity of treatment remains challenging.